logo
OLO SECURITIES NEWS: Did the Olo Inc. (NYSE:OLO) Board Breach its Duties to Shareholders? Contact BFA Law about the Thoma Bravo Merger

OLO SECURITIES NEWS: Did the Olo Inc. (NYSE:OLO) Board Breach its Duties to Shareholders? Contact BFA Law about the Thoma Bravo Merger

NEW YORK, July 20, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Olo Inc. (NYSE: OLO), its board of directors, its executive officers, and founder and current CEO Noah H. Glass for potential breaches of their fiduciary duties to shareholders in connection with the pending sale of Olo to Thoma Bravo Discover Fund IV, L.P. ('Thoma Bravo') for $10.25 per share.
If you are a current shareholder of Olo, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/olo-inc-merger-investigation.
Why is Olo being Investigated?
Olo is an open SaaS platform for restaurants that powers restaurant brands' on-demand digital commerce operations, enabling digital ordering, delivery, engagement, and payments. Olo common stock is divided into Class A and Class B shares. Class A shares are publicly traded, whereas Class B shares are not. Class B shares receive ten votes per share, while Class A shares receive only one vote. As of December 31, 2024, 'directors and executive officers and their affiliates collectively beneficially owned, in the aggregate, shares representing approximately 82% of the voting power of our outstanding capital stock.'
On July 3, 2025, Olo announced that it had entered into a definitive agreement to be acquired by Thoma Bravo in an all-cash transaction valuing Olo at approximately $2 billion in equity value. Under the terms of the agreement, Olo shareholders will receive $10.25 per share in cash. The per-share purchase price purportedly represents a premium of 65% over Olo's unaffected share price of $6.20 as of April 30, 2025.
BFA Law is investigating whether Olo's board of directors, its executive officers, and/or Glass breached their fiduciary duties to shareholders in connection with the merger.
Click here for more information: https://www.bfalaw.com/cases-investigations/olo-inc-merger-investigation.
What Can You Do?
If you are a current holder of Olo you may have legal options and are encouraged to submit your information to the firm.
All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
Submit your information by visiting:
https://www.bfalaw.com/cases-investigations/olo-inc-merger-investigation
Or contact:
Ross Shikowitz
[email protected]
212-789-3619
Why Bleichmar Fonti & Auld LLP?
BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named 'Elite Trial Lawyers' by the National Law Journal, among the top '500 Leading Plaintiff Financial Lawyers' by Lawdragon, 'Titans of the Plaintiffs' Bar' by Law360 and 'SuperLawyers' by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
https://www.bfalaw.com/cases-investigations/olo-inc-merger-investigation
Attorney advertising. Past results do not guarantee future outcomes.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Dycom Industries (DY) Surged on a Mix of Growth Drivers
Dycom Industries (DY) Surged on a Mix of Growth Drivers

Yahoo

time15 minutes ago

  • Yahoo

Dycom Industries (DY) Surged on a Mix of Growth Drivers

Aristotle Capital Boston, LLC, an investment advisor, released its 'Small Cap Equity Strategy' second quarter 2025 investor letter. A copy of the letter can be downloaded here. The second quarter started with a risk-off environment from the previous quarter, but later regained momentum driven by broad-based elements. In the second quarter, the strategy delivered a return of 3.25% net of fees (3.41% gross of fees) underperforming the 8.50% total return of the Russell 2000 Index. For more information on the fund's best picks in 2025, please check its top five holdings. In its second quarter 2025 investor letter, Aristotle Capital Small Cap Equity Strategy highlighted stocks such as Dycom Industries, Inc. (NYSE:DY). Headquartered in Palm Beach Gardens, Florida, Dycom Industries, Inc. (NYSE:DY) provides contracting services to the telecommunications infrastructure and utility industries. The one-month return of Dycom Industries, Inc. (NYSE:DY) was 6.36%, and its shares gained 45.73% of their value over the last 52 weeks. On July 22, 2025, Dycom Industries, Inc. (NYSE:DY) stock closed at $252.68 per share, with a market capitalization of $7.309 billion. Aristotle Capital Small Cap Equity Strategy stated the following regarding Dycom Industries, Inc. (NYSE:DY) in its second quarter 2025 investor letter: "Dycom Industries, Inc. (NYSE:DY), a provider of engineering and construction services to the telecommunications and cable television industries, benefitted from continued growth in its core business, funding tailwinds, and expanding margins as demand for wireline services continues to grow. We maintain our position as we believe the company remains well positioned for longer-term growth alongside secular trends for expanding fiber deployments to support faster broadband connectivity speeds and opportunities to deploy fiber to rural or underserved areas across the country." A 360 degree view of a partially constructed tower, featuring various pieces of equipment and constructionmaterials. Dycom Industries, Inc. (NYSE:DY) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 36 hedge fund portfolios held Dycom Industries, Inc. (NYSE:DY) at the end of the first quarter, which was 37 in the previous quarter. In the fiscal first quarter of 2026, Dycom Industries, Inc. (NYSE:DY) reported $1.259 billion in revenue, reflecting a 10.2% increase over Q1 2025. While we acknowledge the potential of Dycom Industries, Inc. (NYSE:DY) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered Dycom Industries, Inc. (NYSE:DY) and shared best Russell 2000 stocks that have garnered recommendations from Wall Street analysts. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio

MasterCard price target lowered to $612 from $640 at Truist
MasterCard price target lowered to $612 from $640 at Truist

Yahoo

time15 minutes ago

  • Yahoo

MasterCard price target lowered to $612 from $640 at Truist

Truist lowered the firm's price target on MasterCard (MA) to $612 from $640 and keeps a Buy rating on the shares. Truist likes the setup for the FinTech sector as earnings results in totality should be solid, and the group has underperformed of late, the analyst tells investors in a research note. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on MA: Disclaimer & DisclosureReport an Issue Here's what Wall Street experts are saying about GM and Ford ahead of earnings American Airlines, MasterCard announce extension of partnership Japan Just Found a Way to Earn XRP Without Spending a Yen Starbucks downgraded, Oracle initiated: Wall Street's top analyst calls MasterCard resumed with a Buy at Deutsche Bank Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Boston Scientific lifts annual profit view on steady heart devices demand
Boston Scientific lifts annual profit view on steady heart devices demand

Yahoo

time15 minutes ago

  • Yahoo

Boston Scientific lifts annual profit view on steady heart devices demand

(Reuters) -Boston Scientific raised its annual profit forecast on Wednesday, after strong demand for its heart devices helped the U.S. medical device maker beat second-quarter profit estimates. Shares of the Massachusetts-based company rose 2.3% in premarket trading following the results. A rise in surgical procedures has benefited medical device manufacturers such as Boston Scientific, as it boosted sales and helped offset broader concerns about healthcare spending pressures. Analysts said hospital utilization trends were robust during the second quarter, with hospital checks pointing to high single-digit volume growth - well above the historical average. Boston Scientific's main growth drivers, Farapulse and Watchman, which use short high-voltage pulses to treat certain abnormal heart rhythm conditions, saw strong demand during the quarter. Farapulse, approved in the U.S. to treat certain patients with intermittent atrial fibrillation, competes with Johnson & Johnson's Varipulse and Medtronic's PulseSelect in the market for pulsed field ablation (PFA) systems. "Cardiovascular end-markets remain robust," Truist analyst Richard Newitter said ahead of the earnings, adding that Boston, followed by Medtronic, are in the best position at the moment to benefit from the growing and accelerating PFA market. Rival Johnson & Johnson last week posted strong medtech sales, aided by its heart devices, Varipulse and Trupulse. Boston Scientific expects 2025 adjusted profit of $2.95 to $2.99 per share, up from the prior view of $2.87 to $2.94 earlier. It posted adjusted profit of 75 cents per share for the second quarter, topping analysts' average estimate of 72 cents, according to data compiled by LSEG. The company's cardiovascular unit reported quarterly sales of $3.34 billion, surpassing estimates of $3.20 billion. Revenue came in at $5.06 billion for the quarter, topping estimates of $4.9 billion.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store